- Home
- NAGE vs SABS Comparison
NAGE vs SABS Comparison
Compare NAGE & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAGE | SABS |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United States |
| Employees | 117 | 86 |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.2M | 288.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NAGE | SABS |
|---|---|---|
| Price | $3.36 | $3.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $16.00 | $10.75 |
| AVG Volume (30 Days) | 667.9K | ★ 830.5K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.51 | N/A |
| Revenue Next Year | $14.58 | N/A |
| P/E Ratio | $21.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.29 | $1.67 |
| 52 Week High | $14.66 | $6.60 |
Technical Indicators
Market Signals| Indicator | NAGE | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 41.90 | 55.12 |
| Support Level | $3.35 | $3.48 |
| Resistance Level | $4.04 | $4.10 |
| Average True Range (ATR) | 0.15 | 0.24 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 37.74 | 61.80 |
Price Performance
Historical ComparisonAbout NAGE Niagen Bioscience Inc.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.